Clinical profile of early-onset Parkinson’s disease
Objective: Describe motor and non-motor symptoms, complications and treatment in patients with early-onset Parkinson's disease (EOPD) Background: PD usually affecting people over age 60, clinically…Characterisation of the pharmacokinetic profile of amantadine in the common marmoset
Objective: To determine the pharmacokinetic (PK) profile of amantadine in the common marmoset (Callithrix jacchus). Background: Amantadine is currently approved for the treatment of L-3,4-dihydroxyphenylalanine…Efficacy and Safety of Amantadine in Parkinson’s Disease with Dyskinesia and Motor Fluctuations: A Systematic Review and Meta-Analysis
Objective: To evaluate the efficacy and safety of oral amantadine (AMA) compared to placebo in the treatment of dyskinesia (DYS) and motor fluctuations (MF) in…Pharmacokinetic-Pharmacodynamic Modeling of Amantadine Extended-Release Capsule Effects on Dyskinesia in Parkinson Disease
Objective: Evaluate pharmacokinetic/pharmacodynamic (PK/PD) relationships for the delayed- and extended-release (DR/ER) capsule formulation of amantadine [1] in the treatment of levodopa-related dyskinesia in Parkinson disease.…A Case of Paradoxical Gait Response to Levodopa in Parkin-Gene-Related Early-Onset Parkinson’s Disease
Objective: We present a case with a paradoxical gait response to levodopa in Parkin gene-related early-onset Parkinson's Disease. Background: Parkin (PRKN) mutations are the predominant…Miniscope-based neural circuit profiling in freely behaving animals for preclinical therapeutic assessment
Objective: To advance translational research by revealing detailed relationships between neural circuit activity and behavioural symptoms in preclinical models Background: Conventional preclinical tests for CNS…Delayed movement disorders after usage of desomorphine-“crocodile”. Clinical case.
Objective: To study the clinical and neuroimaging features of a patient with a long-term use (more than 10 years) of desomorphine in the anamnesis. Background:…Craniofacial Myoclonus: A Disabling Complication of Amantadine Therapy
Objective: We describe a patient who developed amantadine-induced craniofacial myoclonus with speech impairment. Few cases have been reported [1], thus we offer an additional case…Decreased occurrence of dyskinesia when combining amantadine to L-DOPA in early Parkinson disease (PD): the PREMANDYSK trial
Objective: To assess amantadine effects on dyskinesia and other PD symptoms when adjunct to L-DOPA in early PD. Background: Amantadine is efficacious on L-DOPA-induced dyskinesia…Utilization pattern and factors associated with amantadine use in Parkinson’s disease (PD) of the French NS-Park cohort
Objective: To assess amantadine use in the French NS-Park cohort and factors associated with its prescription Background: Amantadine, a unique dopamine/glutamate drug, is approved worldwide…
- 1
- 2
- 3
- …
- 5
- Next Page »